This summary was created by AI, based on 1 opinions in the last 12 months.
Experts have mixed opinions on the stock, with one recommending selling half of the holdings, while another predicts a potential buyout by Novartis. The soaring shares are based on rumours, indicating a level of uncertainty. Investors should approach with caution and consider potential risks before making any decisions.
Cytokinetics is a American stock, trading under the symbol CYTK-Q on the NASDAQ (CYTK). It is usually referred to as NASDAQ:CYTK or CYTK-Q
In the last year, 1 stock analyst published opinions about CYTK-Q. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Cytokinetics.
Cytokinetics was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Cytokinetics.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year, there was no coverage of Cytokinetics published on Stockchase.
On 2024-08-30, Cytokinetics (CYTK-Q) stock closed at a price of $57.06.
Shares have soared lately on rumours that Novartis will by them out. Sell half your holding and let the rest run.